Hype surrounding the psychedelic drug ibogaine reached a fever pitch in April when President Donald Trump talked up its potential at a White House event promoting psychedelics. However, experts warn that enthusiasm is outpacing scientific evidence, and more rigorous research is needed before expanded access becomes available.
Current Research Limitations
While a few encouraging studies suggest ibogaine has therapeutic potential, they are very small and typically observational. The most-cited Stanford University study enrolled just 30 veterans and found ibogaine nearly eliminated symptoms of PTSD, depression, and anxiety in combat veterans with traumatic brain injuries. Other research suggests the drug can powerfully reduce cravings in people with substance use disorders, including opioid addiction. However, the only study that appears to have tested ibogaine against a placebo included just 20 people seeking help for cocaine addiction. Before this drug can treat complex mental health conditions, larger, more rigorous trials must prove it works, define who it can help, the magnitude of benefit, and how long effects last.
Serious Safety Concerns
Beyond efficacy questions lies a more urgent issue: ibogaine binds to proteins in the heart, leading some people to experience a dangerously irregular heartbeat. Reviews of clinical research consistently warn against severe medical complications, including heart attacks and even death. FDA Commissioner Marty Makary acknowledged that if approved, ibogaine would need to be provided in “a very controlled and supervised medical, clinical setting.” Yet multiple experts doubt ibogaine could ever be widely used, given its potential for harm.
Path Forward
The federal government should invest not just in clinical studies, but in basic research to understand how ibogaine works. Researchers have made great strides understanding how LSD and psilocybin interact with the brain, but ibogaine remains more of a mystery. The drug is known to act on a range of receptors, but scientists have yet to parse which are responsible for potentially beneficial effects. Insight into ibogaine’s basic pharmacology could allow scientists to design better versions that maintain therapeutic effect while tuning out cardiac risks.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.newsday.com/opinion/commentary/ibogaine-dd7806ic